Clinical adverse events to voclosporin: a real-world drug safety study based on FDA Adverse Event Reporting System
The present research provides a significant assessment of the postmarketing safety profile of voclosporin. However, additional studies are needed to corroborate and solidify these observations. Clinicians are advised to remain highly vigilant about the potential AEs associated with voclosporin and to carefully consider the appropriate dosing regimens when utilising this medication in clinical practice.
Authors
- Ruxuan Chen (ORCID: https://orcid.org/0000-0002-8808-5322)
- Liheng Liu (ORCID: https://orcid.org/0000-0002-3666-279X)
- Hui Huang (ORCID: https://orcid.org/0000-0001-7184-0005)
- Jiaqi Zhang (ORCID: https://orcid.org/0000-0001-7798-3816)
- Pingping Li (ORCID: https://orcid.org/0000-0003-0679-270X)
- Yanjun Wan
- Yujie Shi
- Yan Tang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-02-23
- DOI
- https://doi.org/10.55563/clinexprheumatol/qhyux8
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00